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Objective
• To assess the impact of histotripsy treatment parameters
(pulse number and pulse-repetition frequency [PRF]) on the
eﬃciency of histotripsy induced homogenisation of the
prostatic urethra.
Materials and Methods
• In all, 34 transabdominal prostate histotripsy treatments
were applied along a perpendicular plane traversing the
prostatic urethra of 21 dogs.
• Prostate histotripsy was applied with (i) escalating pulse
number with ﬁxed PRF or (ii) at ﬁxed pulse number with
varying PRFs.
• The development of urethral homognisation ≤14 days of
histotripsy was evaluated endoscopically and conﬁrmed
histologically.
Results
• Within 14 days of histotripsy 50%, 83%, 83%, and 100%
of dogs receiving 12 500, 25 000, 50 000, and 100 000
pulses/mm of treatment path (delivered at 500 Hz PRF),
respectively developed prostatic urethral disintegration.
• Delivery of 100 000 pulses/mm was required to achieve
urethral disintegration in all dogs within 24 h of histotripsy
treatment.
• Increasing histotripsy PRF from 50 to 500 to 2000 Hz while
applying a constant dose of 25 000 pulses/mm treatment
was associated with increased rate of urethral disintegration
(50% vs 75% vs 100% at 14 days, respectively).
Conclusions
• Increasing the number of histotripsy pulses and/or
increasing the PRF of histotripsy treatment applied to the
urethra may improve the rate and eﬃciency of prostatic
urethral disintegration in the canine model.
• This understanding will aid in the development of
treatment strategies for prostate histotripsy for benign
prostatic hyperplasia in human trials.
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Introduction
Histotripsy is a focused ultrasound technology that delivers
short (<50 μs), intense pulses of acoustic energy at low duty
cycle to induce microbubble formation within a deﬁned
geometric focal volume while minimising thermal eﬀects
[1–5]. The oscillation and collapse of these bubbles
mechanically homogenises targeted tissues into a ﬁne slurry of
acellular debris [1,6,7]. Analysis of the homogenate has
revealed that >99.9% of particles are <6 μm [8]. Volumetric
ablation of greater than the size of a single focal volume is
accomplished by moving the bubble cloud throughout the
targeted region. Histotripsy therapy can be guided and
monitored in real-time with conventional ultrasound because
the bubble cloud appears as a distinct hyperechoic (bright)
focus and targeted tissue echogenicity decreases (becomes
darker) corresponding to progressive tissue disintegration
[9,10]
The main objective of this research is to develop a histotripsy
therapy for BPH that replicates the debulking capability of
TURP, yet is less invasive and hence more widely applicable to
patients with signiﬁcant co-morbidity and/or suitable for use
outside the operating room. Towards this goal, histotripsy has
been evaluated in an in vivo canine model, demonstrating the
ability to homogenize prostate tissue [11]. In this model,
transabdominal histotripsy of the prostate appears safe and
eﬀective [12], producing dose-dependent tissue debulking of
targeted prostatic tissue [13] with minimal haematuria, even in
anticoagulated dogs [14]. The strategy for eﬀective histotripsy
treatment of BPH is to produce a TURP-like defect by
homogenising parenchymal tissue as well as the adjacent
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prostatic urethra to facilitate drainage of the resultant
homogenate with voiding [12]. However, the prostatic urethra
is more resilient to mechanical forces than the prostate
parenchyma and requires a greater number of acoustic pulses
to achieve tissue disintegration [13]. In vitro studies have also
shown that substrate stiﬀness is inversely correlated with
histotripsy susceptibility and lesion size [15] and that altering
the pulse-repetition frequency (PRF) can aﬀect the eﬃciency
of cavitation-induced tissue homogenisation [16]. As a result,
the purpose of the present study was to explore the eﬃciency
of prostatic urethra homogenisation in an in vivo canine
model when varying the number and rate (PRF) of applied
histotripsy pulses to better optimise treatment parameters in
anticipation of future clinical applications.
Material and Methods
After receiving approval from the University Committee for
Animal Use and Care, 21 intact male mongrel dogs weighing
25.0–33.6 kg were obtained. Intramuscular penicillin G
benzathine (40 000 IU/kg) was administered before the
procedure and on postoperative days (POD) 3 and 7 for
prophylaxis. Carprofen (2.2 mg/kg/day) was administered
orally before and for 24 h after the procedure for analgesia.
The dogs were anaesthetised with acepromazine (0.1 mg/kg,
s.c.) and propofol (2–8 mg/kg, i.v.) and intubated. After
intubation each dog underwent digital disimpaction and tap
water enema, was positioned supine, and the abdomen and
suprapubic region were shaved. Inhalational anaesthesia
(isoﬂurane 1–2%) was maintained throughout treatment.
Flexible endoscopy was performed with an 8.2-F ﬂexible
ureteroscope (Dur-8, Gyrus ACMI) before histotripsy
treatment to document a normal lower urinary tract and to
serve as an intrasubject control.
TRUS imaging was performed using a Logiq 6 ultrasound
scanner (GE Healthcare,Waukesha,WI, USA) with a model
ERB probe positioned in a custom holder. Prostatic volume
was computed using a stepper volume technique by
contouring the prostate margin on transverse slices at 2.5-mm
intervals. The therapeutic histotripsy system consists of a
16-element piezoceramic composite array (750 kHz, 11 ×
14-cm diameter oval shape, focal length 10 cm, focal volume 3
× 3 × 8 mm (Fig. 1A; Imasonic, Voray sur l’Ognon, France)
on a three-axis computer-controlled positioning system
(MATLAB, MathWorks, Natick, MA, USA). Coupling was
achieved by placing the therapy transducer in a bath of
degassed water contained in a plastic membrane in direct
contact with the shaved abdomen (Fig. 1B). In all, 21 dogs
underwent treatment with histotripsy pulses consisting of
ﬁve cycle (6.7 μs) bursts of acoustic energy delivered at a
prescribed PRF for a speciﬁed number of pulses. During each
treatment, the histotripsy bubble cloud was translated along a
single transverse plane that intersected the urethra and
periurethral tissues as previously described [17] (Fig. 1C). In
dogs with suﬃciently large prostates, two treatments were
applied at separate locations at least 1 cm apart. In the initial
phase of the study, treatment consisted of 12 500, 25 000,
50 000, or 100 000 pulses/mm of path length at a PRF of
500 Hz to evaluate the eﬀect of the number of histotripsy
pulses on prostatic urethral disintegration. In the second
phase of the study, treatment consisted of applying 25 000
pulses/mm of path length at PRF of 50, 500, 2000 Hz to
evaluate the eﬀect of altering PRF on prostatic urethral
disintegration. A urinary catheter was not placed after
treatment.
After completing histotripsy treatment, cystoscopy was used
to evaluate acute changes in urethral appearance. All dogs
recovered from anaesthesia and were monitored for
treatment-related adverse events. Cystoscopy was repeated on
POD 1, 3, 7, and then at euthanasia on POD 14. TRUS was
repeated on POD 7 under anaesthesia and at the time of
euthanasia with i.v. pentobarbital sodium 140–160 mg/kg. A
suprapubic incision was then made and a cystotomy created
through which antegrade cystourethroscopy was performed
using a 16-F ﬂexible cystoscope (Cy2, Olympus). The prostate,
Fig. 1 Histotripsy experimental setup: During treatment the transducer (A)
is lowered into a bath of degassed water in direct contact with abdomen
(B). Treatment was targeted along a plane transecting the urethra (C).
A
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bladder and adjacent rectum were surgically removed en bloc
and inspected grossly for injury. Tissues were ﬁxed in
formalin for 1 week, cut into 5-mm thick slices, dehydrated in
25% ethanol, paraﬃn embedded, cut using a microtome in
5-μm sections at 1 mm increments, mounted, and stained with
haematoxylin and eosin for histological assessment.
Cumulative rates of urethral disintegration stratiﬁed by
treatment parameters (number of pulses and PRF) were
plotted graphically for interpretation.
Results
In all, 34 prostate histotripsy treatments were performed in 21
dogs. The mean (range) prostate volume before histotripsy
was 22.2 (10.5–52.8) mL. During treatment, the cavitation
bubble cloud was well visualised on TRUS (Fig. 2) and the
targeted periurethral parenchymal tissue became progressively
hypoechoic, while the prostatic urethra appeared structurally
intact throughout treatment despite intraluminal cavitation.
Immediately after histotripsy (POD 0), endoscopic assessment
of the prostatic urethra/treatment plane showed punctate
haemorrhage, shaggy urothelium, tissue ﬂaps and in some
cases gross disintegration. In dogs undergoing two treatments,
there was an intervening band of normal appearing prostatic
urethra between treatments. Acute (POD 0) gross urethral
disintegration was endoscopically apparent in only four of 34
(11.8%) treatment zones immediately after treatment, but
developed in 27/34 (79.4%) by POD 14.
Treatment planes that did not develop gross urethral
disintegration by POD 14 were seen on TRUS to have
persistent internal echoes and/or gravity ﬂuid/debris levels
within the targeted adjacent periurethral parenchyma
suggesting undrained homogenate. Conversely, planes with
cavities communicating with disintegrated urethra had absent
or minimal internal echoes consistent with drainage of the
homogenised material via the urethra. These ﬁndings were
conﬁrmed histologically (Fig. 3).
Application of more histotripsy pulses (at PRF of 500 Hz)
resulted in an increased likelihood of urethral disintegration
Fig. 2 TRUS appearance of prostate histotripsy therapy: Early in treatment
the histotropsy bubble cloud (arrow) is visualised adjacent to the urethra
(outlined circle) (A). During treatment the targeted region becomes
progressively hypoechoic producing a hypoechic cavity (*) adjacent to




Fig. 3 Endoscopic appearance of urethral disintegration on POD14 (A) with confirmatory low- (B) and high-power (C) micrographs showing drainage
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and generally earlier presentation of urethral disintegration
(Fig. 4). Speciﬁcally, by POD 14 urethral disintegration
occurred in 50%, 83%, 83%, and 100% of subjects receiving
12 500, 25 000, 50 000, and 100 000 pulses/mm of treatment
path, respectively.While immediate prostatic urethral
disintegration was rare it did occur within 24 h of treatment in
all the dogs receiving the 100 000 pulses/mm treatment. For
histotripsy pulse delivery at varying PRF (50, 500, and
2000 Hz) and constant pulse number (25 000 pulses/mm),
increasing treatment PRF to 2000 Hz was associated with
100% urethral disintegration by POD 14, compared with 75%
for 500 Hz and 50% for 50 Hz (Fig. 5).
Complications included rectoprostatic ﬁstula in two dogs
and development of intraperitoneal urinoma in two dogs
secondary to prostatic urethral and capsular perforation.
Discussion
Over the last several decades, minimally invasive ablative
therapies have been introduced in an eﬀort to reduce the
morbidity associated with TURP. Previous attempts to
accomplish this goal with transurethral needle ablation
(TUNA) and microwave forms of energy failed to replicate the
eﬃcacy and durability of TURP (possibly due to lack of tissue
debulking) [18,19]. High-intensity focussed ultrasound
(HIFU) has been extensively investigated in Europe and Asia
for transrectal treatment of disorders of the prostate. HIFU
delivers long (3–5 s) pulses of acoustic energy to thermally
coagulate the targeted tissue volume [20].While outcomes are
encouraging for prostate cancer [21,22]; previous work
attempting to use HIFU for treating BPH has ultimately
proven to be unsuccessful, as nearly 45% of patients required
TURP ≤4 years of HIFU treatment [23]. In this clinical setting,
TRUS conﬁrmed TURP-like defects in only 25–30% of cases
after HIFU [24], raising concern about adequate tissue
debulking. The authors postulated that three factors may have
contributed to the poor durability: (i) inadequate volume of
targeted tissue necrosis, (ii) necrotic treatment area evolved
into scar possibly increasing ﬁbrosity within the prostate and
preventing improvement of urinary symptoms, and (iii)
obstructive tissue at the bladder neck was not suﬃciently
treated to relieve obstruction [23].
In preclinical studies, histotripsy has been shown to
homogenise and debulk prostate tissue in the in vivo canine
model [11–13]. Based on these results, creating a TURP-like
defect with histotripsy appears feasible; however, the optimal
treatment strategy to reliably and eﬃciently achieve this goal is
unknown, in part because the prostatic urethra is more
resilient to mechanical tissue eﬀects than prostate parenchyma
[13]. To best explore prostatic urethral tissue response to a
range of acoustic pulse parameters, histotripsy was applied
along a linear path perpendicularly traversing the urethra. This
simpliﬁed the treatment environment (minimising the impact
of factors such as acoustic shielding from the pubis and os
penis) allowed for multiple treatments per prostate in
appropriate subjects. As the size of the cavitation bubble cloud
varies with tissue medium, acoustic aperture, and pulse
repetition frequency [2] this treatment strategy does not allow
calculation of treatment density (pulses/volume treatment)
making comparisons of treatment densities in the present
study to previous work diﬃcult. Instead, ‘histotripsy dose’ was
reported as the number of pulses applied per mm of
transverse treatment path.
Using this treatment strategy with a PRF of 500 Hz, histotripsy
doses of 100 000 pulses/mm treatment were required to
achieve urethral disintegration within 24 h of treatment in all
dogs and doses of ≥25 000 pulses/mm treatment were
required to achieve urethral disintegration in at least 80% of
dogs ≤2 weeks of treatment. Qualitatively, these treatment
doses were well above the threshold to induce homogenisation
of the adjacent periurethral prostatic parenchyma, which
consistently showed increased sensitivity to histotripsy
treatment eﬀects compared with the urethra on
Fig. 4 Cumulative development of prostatic urethral disintegration with
histotripsy treatment with 12 500–100 000 pulses/mm with constant PRF
(500 Hz).
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Fig. 5 Cumulative development of prostatic urethral disintegration at PRF
of 50, 500, and 2000 Hz with constant treatment dose (25 000
pulses/mm).
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intra-treatment TRUS. Histology conﬁrmed this observation
with the presence of undrained homogenised prostatic tissue
in all dogs, which failed to achieve disintegration of the
adjacent prostatic urethra consistent with previous data
[13,17]. Further, in such cases, the intact adjacent urethra
appeared completely normal despite the adjacent parenchymal
damage.
While direct tissue homogenisation is clearly of importance to
the mechanism of action of histotripsy [3,6,7], factors other
than treatment dose probably contribute to successful tissue
homogenisation. One such factor is PRF, as data suggest
modifying PRF during histotripsy treatment may alter the
eﬃciency of tissue erosion [25]. Interestingly, in the present
study, altering PRF did not appear to substantially impact the
development of urethral disintegration ≤24 h of treatment.
However, there was an increase in urethral disintegration 14
days after treatment as PRF was increased from 50 to 500 to
2000 Hz (50% vs 75% vs 100%, respectively). This observation,
if conﬁrmed by larger studies, was unexpected based on in
vitro data suggesting that increased PRF is associated with
decreased eﬃciency of tissue homogenisation, sporadic
cavitary damage, and increased number of pulses to achieve
equivalent damage in both myocardium and liver [16,26]. One
possible explanation for the greater rate of delayed urethral
disintegration at higher PRF is that the larger bubble-cloud
produced by increasing PRF may lead to a larger ﬁeld of
incompletely homogenised, yet lethal tissue damage, that when
remodelled in the chronic setting leads to overall higher rates
of urethral disintegration.
While the prostatic urethra is more resistant to histotripsy
than the parenchyma/adenoma, the basis of its resistance is
unknown. In vitro studies, examining lesion size in agar have
shown that lesion size is directly related to duration of
treatment (number of pulses) and inversely related to ‘tissue’
stiﬀness [15]. Histologically, the prostatic urethra (and its
periurethral ﬁbromuscular) stroma contains more collagen
than the surrounding prostatic parenchyma, suggesting
increased tissue strength and ‘stiﬀness’ compared with the
parenchyma. As a result, the increased collagen content of the
prostatic urethra may contribute to the higher threshold for
histotripsy induced tissue disintegration, a hypothesis that is
actively being evaluated. Aside from decreased sensitivity of
the urethra to the eﬀects of histotripsy, an additional possible
explanation of failure to disintegrate the urethra is inadequate
urethral targeting. However, using real-time
cystourethroscopy, we have previously shown the presence of
histotripsy induced intraluminal cavitation using the same
treatment strategy [17] suggesting adequate urethral targeting.
Although the results from the present study will help guide
future histotripsy research, they are not without limitations,
most importantly their generalizability to humans. However,
the prostate is very similar between both species with the
arterial supply originating from the internal pudendal artery,
and branches perforating the capsule to supply the stroma and
glandular tissues. Structurally, while the canine prostate is
bi-lobed without zonal structures, the human prostate is
subdivided into several zones, with potentially diﬀerent
treatment thresholds, with the transition zone being most
relevant to BPH [27]. Additionally, the intraperitoneal location
of the canine prostate lends itself to a transabdominal
histotripsy approach, whereas structural modelling suggests
that the human prostate will probably be more amenable to a
transperineal approach [28]. The transabdominal approach
combined with small prostate size probably contributed to the
complications in the present study – the cigar shaped
histotripsy bubble cloud was perpendicular to the axis of the
urethra making adequate targeting of the urethra while
attempting to maintain the bubble cloud within the
parenchyma along the midline sulcus diﬃcult in some dogs,
thus increasing the risk of rectal injury and prostatic capsular
perforation. Ultimately, human studies are needed to
determine both the clinical eﬃcacy and optimal treatment
algorithm for prostate histotripsy for BPH.
In summary, extracorporeal application of histotripsy to the
prostate is capable of homogenising targeted prostate
parenchyma with subsequent creation of a TURP-like defect.
Increasing the number of histotripsy pulses and/or increasing
the PRF of these pulses applied to the urethra appears to
improve the rate and eﬃciency of prostatic urethral
disintegration in the canine model, which may facilitate
drainage of the homogenate and enhance prostate debulking.
This understanding will prove useful in developing treatment
strategies for prostate histotripsy treatment of BPH in human
trials.
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